🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yingdong Zhao

National Cancer Institute

ORCID: 0000-0002-8514-0293
Immunology and MicrobiologyBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.2Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

MutSpliceDB: A database of splice sites variants with RNA‐seq based evidence on effects on splicing

Human Mutation(2021)10.1002/humu.24185
Top 21%
0.973DataRank
Top 21%21 citations

Suleyman Vural, Yingdong Zhao, Dmitriy Sonkin, Alida Palmisano

Papers

Driven by 15 papers — median percentile 58. Top paper: “MutSpliceDB: A database of splice sites variants with RNA‐seq based evidence on effects on splicing”.

MutSpliceDB: A database of splice sites variants with RNA‐seq based evidence on effects on splicing

Human Mutation(2021)10.1002/humu.24185
Top 21%
0.973DataRank
Top 21%21 citations

Suleyman Vural, Yingdong Zhao, Dmitriy Sonkin, Alida Palmisano

Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines

Clinical Epigenetics(2022)10.1186/s13148-022-01368-7
N/A
0.296DataRank · unranked
5 citations

Suleyman Vural, Travis L. Jensen, George W. Wright, Yingdong Zhao, Julia Krushkal

TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs

Bioinformatics(2021)10.1093/bioinformatics/btab619
Top 62%
0.225DataRank
Top 62%3 citations

Alida Palmisano, Ravindra Kumar, Ming‐Chung Li, James H. Doroshow, Yingdong Zhao +1 more

Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity

UNC Libraries(2021)10.17615/r866-gv64
N/A
0DataRank · unranked
4 citations

Mike Schutkowski, Hengming Ke, Gunter Fischer, Yingdong Zhao, Yong Q. Chen

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products

Journal of Translational Medicine(2022)10.1186/s12967-022-03729-5
N/A
0DataRank · unranked
51 citations

Rongye Shi, Yingdong Zhao, Hui Liu, Alexander Lu, Jinxia Ma +13 more

Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts

Scientific Reports(2022)10.1038/s41598-022-23693-w
N/A
0DataRank · unranked
4 citations

Ming‐Chung Li, Lisa M. McShane, Yingdong Zhao, Mariam M. Konaté

Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products

BMC Cancer(2022)10.1186/s12885-022-09580-7
N/A
0DataRank · unranked
5 citations

Simarjeet Negi, Lisa M. McShane, Yingdong Zhao, Julia Krushkal, Hari Sankaran

Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy

Scientific Reports(2022)10.1038/s41598-022-06830-3
N/A
0DataRank · unranked
4 citations

Avinash Iyer, Yingdong Zhao, R.P. Somerville, Sandhya R. Panch, Alejandra Pelayo +3 more

Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation

Biomolecules(2023)10.3390/biom13101499
N/A
0DataRank · unranked
14 citations

Yingdong Zhao, Ming‐Chung Li, Joanna H. Shih, Will Jiang, Erdal Taşçı +7 more

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Epigenetics(2024)10.1080/15592294.2024.2309824
N/A
0DataRank · unranked
6 citations

Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker +4 more

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

Frontiers in Oncology(2025)10.3389/fonc.2025.1571635
N/A
0DataRank · unranked
1 citations

Sergio Y. Alcoser, MICHAEL E. MULLENDORE, Li Chen, Chih-Jian Lih, Vishnuprabha Rahul Kannan +18 more

Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products

Molecular Oncology(2020)10.1002/1878-0261.12849
N/A
0DataRank · unranked
29 citations

Simarjeet Negi, Laura M. Yee, Jason R. Evans, Tanja Grkovic, Alida Palmisano +6 more

Serum p-Cresol and 7-HOCA Levels and Fatty Acid and Purine Metabolism Are Associated with Survival, Progression, and Molecular Classification in GB—Serum Proteome and Metabolome Analysis Pre vs. Post Up-Front Chemoirradiation

Current Oncology(2025)10.3390/curroncol32110650
N/A
0DataRank · unranked
0 citations

M. Li, Yingdong Zhao, Erdal Taşçı, Shreya Chappidi, Theresa Cooley Zgela +4 more

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Journal of Translational Medicine(2021)10.1186/s12967-021-02936-w
N/A
0DataRank · unranked
524 citations

Ming‐Chung Li, Mariam M. Konaté, Li Chen, Biswajit Das, Chris Karlovich +5 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372
N/A
0DataRank · unranked
45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more